<DOC>
	<DOCNO>NCT01962935</DOCNO>
	<brief_summary>Study investigate safety , tolerability effect multiple dosing AZD 4721 and/or AZD 5069</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability Effect Multiple Dosing With AZD 4721 and/or With AZD 5069</brief_title>
	<detailed_description>The purpose study investigate safety tolerability , pharmacokinetics pharmacodynamics AZD 4721 healthy volunteer daily administration multiple ascend dos 10 day , open-label comparison pharmacodynamics AZD5069 give twice daily 3 day</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1.Provision sign date , write informed consent prior study specific procedure . 2.Healthy male and/or female Caucasian ( neither Black/African American Japanese ) volunteer age 18 50 year suitable vein cannulation repeat venipuncture . ( `` Healthy '' determine medical history physical examination , clinical laboratory parameter , ECG perform first dose administration. ) . 3.Healthy volunteer body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) weigh least 50 kg 100 kg ( inclusive ) . 1 . Pyrexial body temperature high 37.7Â°C Day 1 ( Visit 2 ) , judge investigator . 2 . Screening blood neutrophil count ( take morning ) within laboratory reference range ( Visit 1 ) . 3 . Other latent chronic infection ( eg , recurrent sinusitis , genital ocular herpes , urinary tract infection ) risk infection ( surgery , trauma , significant infection ) previous 90 day , history skin abscess within previous 90 day . 4 . Clinically significant low respiratory tract infection resolve within 4 week prior screen ( Visit 1 ) , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Multiple ascend dose</keyword>
</DOC>